Phenyl-Substituted Nicotinic Ligands for Selective α4β2 Receptor Desensitization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nicotine addiction, such as varenicline, have temporary effects and adverse side effects, limiting their therapeutic use, and there is a need for more effective and selective compounds that target α4β2 nicotinic acetylcholine receptors to address various central nervous system disorders.
Innovation Solution
Development of a new class of nicotinic acetylcholine receptor ligands with high selectivity and picomolar binding affinity for α4β2 receptors, specifically VMY-2-95, which potently desensitizes α4β2 receptors and reduces nicotine self-administration in animal models, offering potential therapeutic benefits for addiction and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If varenicline is used to treat nicotine addiction, then nicotine craving is reduced, but the treatment has temporary effects and adverse side effects
Solution Approach 1:
The patent modifies the chemical structure of known nAChR ligands by introducing specific substituents and functional groups to create compounds with altered binding properties. This structural parameter change aims to achieve longer duration of action and reduced side effects while maintaining therapeutic effectiveness at the α4β2 receptor target
Solution Approach 2:
The invention combines multiple pharmacological properties in a single compound by designing molecules that simultaneously exhibit high affinity binding, selective desensitization, and prolonged duration of action. This composite approach integrates multiple desired characteristics into one therapeutic agent to overcome the limitations of existing treatments
2Reliability
If current nAChR ligands are used, then some therapeutic effect is achieved, but selectivity for α4β2 receptors is insufficient
Solution Approach 1:
The patent introduces specific local modifications to the ligand structure, such as particular substituents at defined positions on the core scaffold. These localized structural changes enhance binding selectivity for the α4β2 receptor subtype while minimizing interactions with other nAChR subtypes, thereby improving therapeutic specificity
3Reliability
If nicotine is administered, then nAChRs are activated, but desensitization requires chronic administration which causes up-regulation
Solution Approach 1:
The patent designs compounds that pre-establish stable desensitized states at nAChR receptors through high-affinity binding. This preliminary action creates a sustained therapeutic effect that prevents receptor up-regulation and maintains desensitization without requiring chronic nicotine administration, thereby extending the duration of therapeutic action
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep.